Loading...

Corbus Pharmaceuticals Holdings

DB:337
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
337
DB
$448M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Corbus Pharmaceuticals Holdings has significant price volatility in the past 3 months.
337 Share Price and Events
7 Day Returns
2.6%
DB:337
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
17.2%
DB:337
-10.2%
DE Biotechs
-6%
DE Market
337 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corbus Pharmaceuticals Holdings (337) 2.6% -7% -6.1% 17.2% - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 337 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 337 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
337
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Corbus Pharmaceuticals Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Corbus Pharmaceuticals Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Corbus Pharmaceuticals Holdings.

DB:337 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:337
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0.09%))
1.301
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.301 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:337 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Corbus Pharmaceuticals Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:337 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -62.00 Analyst x3 -57.42
2020 -87.02 Analyst x3 -74.63
2021 -67.64 Analyst x3 -53.73
2022 50.72 Analyst x3 37.31
2023 256.23 Analyst x3 174.55
2024 434.96 Est @ 69.76% 274.40
2025 647.64 Est @ 48.9% 378.39
2026 869.76 Est @ 34.3% 470.60
2027 1,079.16 Est @ 24.08% 540.75
2028 1,261.77 Est @ 16.92% 585.53
Present value of next 10 years cash flows $2,275.77
DB:337 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,261.77 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$16,314.08
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $16,314.08 ÷ (1 + 7.98%)10
$7,570.69
DB:337 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,275.77 + $7,570.69
$9,846.45
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $9,846.45 / 64.46
$152.76
DB:337 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:337 represents 0.89684x of NasdaqGM:CRBP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89684x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 152.76 x 0.89684
€137.00
Value per share (EUR) From above. €137.00
Current discount Discount to share price of €6.23
= -1 x (€6.23 - €137.00) / €137.00
95.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Corbus Pharmaceuticals Holdings is available for.
Intrinsic value
>50%
Share price is €6.23 vs Future cash flow value of €137
Current Discount Checks
For Corbus Pharmaceuticals Holdings to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Corbus Pharmaceuticals Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corbus Pharmaceuticals Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corbus Pharmaceuticals Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:337 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.98
NasdaqGM:CRBP Share Price ** NasdaqGM (2019-04-18) in USD $6.95
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corbus Pharmaceuticals Holdings.

DB:337 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CRBP Share Price ÷ EPS (both in USD)

= 6.95 ÷ -0.98

-7.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corbus Pharmaceuticals Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Corbus Pharmaceuticals Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Corbus Pharmaceuticals Holdings's expected growth come at a high price?
Raw Data
DB:337 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
54.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Corbus Pharmaceuticals Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corbus Pharmaceuticals Holdings's assets?
Raw Data
DB:337 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.48
NasdaqGM:CRBP Share Price * NasdaqGM (2019-04-18) in USD $6.95
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:337 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CRBP Share Price ÷ Book Value per Share (both in USD)

= 6.95 ÷ 0.48

14.46x

* Primary Listing of Corbus Pharmaceuticals Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corbus Pharmaceuticals Holdings is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Corbus Pharmaceuticals Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Corbus Pharmaceuticals Holdings has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Corbus Pharmaceuticals Holdings expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corbus Pharmaceuticals Holdings expected to grow at an attractive rate?
  • Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the Germany market average.
  • Corbus Pharmaceuticals Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:337 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:337 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 54.3%
DB:337 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 65.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:337 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:337 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 476 324 212 6
2022-12-31 239 70 53 6
2021-12-31 64 -80 -78 5
2020-12-31 9 -83 -84 7
2019-12-31 17 -41 -55 9
DB:337 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -30 -56
2018-09-30 3 -25 -49
2018-06-30 3 -23 -41
2018-03-31 2 -23 -37
2017-12-31 2 -28 -32
2017-09-30 3 -24 -29
2017-06-30 3 -21 -28
2017-03-31 3 -18 -25
2016-12-31 2 -14 -20
2016-09-30 2 -9 -15
2016-06-30 1 -8 -12
2016-03-31 1 -6 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corbus Pharmaceuticals Holdings's earnings are expected to grow significantly at over 20% yearly.
  • Corbus Pharmaceuticals Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:337 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:337 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.88 7.58 1.04 4.00
2022-12-31 0.80 3.53 -0.49 6.00
2021-12-31 -1.15 0.28 -2.33 6.00
2020-12-31 -1.29 -1.00 -1.91 6.00
2019-12-31 -0.95 -0.58 -1.22 8.00
DB:337 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.98
2018-09-30 -0.87
2018-06-30 -0.76
2018-03-31 -0.70
2017-12-31 -0.65
2017-09-30 -0.61
2017-06-30 -0.60
2017-03-31 -0.57
2016-12-31 -0.49
2016-09-30 -0.38
2016-06-30 -0.32
2016-03-31 -0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corbus Pharmaceuticals Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corbus Pharmaceuticals Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corbus Pharmaceuticals Holdings has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corbus Pharmaceuticals Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corbus Pharmaceuticals Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Corbus Pharmaceuticals Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Corbus Pharmaceuticals Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Corbus Pharmaceuticals Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:337 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.82 -55.67 12.96
2018-09-30 2.89 -49.06 11.79
2018-06-30 2.60 -41.42 10.74
2018-03-31 2.10 -36.65 9.63
2017-12-31 2.44 -32.42 8.96
2017-09-30 2.82 -29.30 8.96
2017-06-30 2.76 -27.68 8.59
2017-03-31 2.81 -24.57 7.73
2016-12-31 1.91 -20.00 6.46
2016-09-30 1.90 -14.93 4.93
2016-06-30 1.33 -11.83 3.96
2016-03-31 1.04 -10.21 3.91
2015-12-31 0.65 -8.85 3.61
2015-09-30 0.28 -7.61 3.26
2015-06-30 0.11 -6.02 2.83
2015-03-31 -3.96 2.16
2014-12-31 -2.54 1.39
2014-09-30 -1.57 1.00 -0.02
2014-06-30 -0.97 0.65 0.01
2014-03-31 -0.67 0.37 0.19
2013-12-31 -0.60 0.35 0.21
2012-12-31 -0.89 0.29 0.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Corbus Pharmaceuticals Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Corbus Pharmaceuticals Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Corbus Pharmaceuticals Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corbus Pharmaceuticals Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corbus Pharmaceuticals Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corbus Pharmaceuticals Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corbus Pharmaceuticals Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 112.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corbus Pharmaceuticals Holdings Company Filings, last reported 3 months ago.

DB:337 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 27.52 0.39 41.75
2018-09-30 42.87 0.00 55.66
2018-06-30 55.49 0.08 64.68
2018-03-31 65.54 0.21 70.96
2017-12-31 57.78 0.33 62.54
2017-09-30 31.98 0.00 36.60
2017-06-30 37.59 0.04 43.03
2017-03-31 43.59 0.16 48.93
2016-12-31 8.92 0.28 14.99
2016-09-30 13.31 0.01 18.91
2016-06-30 17.65 0.03 22.03
2016-03-31 6.40 0.10 9.69
2015-12-31 8.99 0.16 12.34
2015-09-30 11.17 0.00 13.17
2015-06-30 6.77 0.00 9.24
2015-03-31 4.69 0.07 4.97
2014-12-31 5.86 0.14 6.26
2014-09-30 7.02 0.08 7.54
2014-06-30 7.45 0.64 8.50
2014-03-31 -0.79 0.64 0.16
2013-12-31 -0.67 0.64 0.30
2012-12-31 -0.20 0.63 0.54
  • Corbus Pharmaceuticals Holdings's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • Corbus Pharmaceuticals Holdings had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Corbus Pharmaceuticals Holdings has sufficient cash runway for 1.3 years based on current free cash flow.
  • Corbus Pharmaceuticals Holdings has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 49.3% each year.
X
Financial health checks
We assess Corbus Pharmaceuticals Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corbus Pharmaceuticals Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corbus Pharmaceuticals Holdings dividends.
If you bought €2,000 of Corbus Pharmaceuticals Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corbus Pharmaceuticals Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corbus Pharmaceuticals Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:337 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:337 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corbus Pharmaceuticals Holdings has not reported any payouts.
  • Unable to verify if Corbus Pharmaceuticals Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corbus Pharmaceuticals Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corbus Pharmaceuticals Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Corbus Pharmaceuticals Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corbus Pharmaceuticals Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corbus Pharmaceuticals Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Corbus Pharmaceuticals Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuval Cohen
COMPENSATION $3,242,269
AGE 43
TENURE AS CEO 5 years
CEO Bio

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc (formerly, Morria Biopharmaceuticals Plc) from February 2013 to June 2013 and served as its President and Co-founder since January 12, 2005 until February 2013. Dr. Cohen served as the Managing Director of Celsus Therapeutics Plc. Dr. Cohen has been the driving force behind transforming MFAID technology into the biotech start-up that is Morria. Dr. Cohen's background in both molecular biology and protein biochemistry and his interest in biotechnology enable him to understand and convey both the nature and potential of this technology. His responsibility is to develop the anti-inflammatory propriety technology platform to its full potential with various strategic partners. Dr. Cohen is committed to making Morria an unprecedented success. Dr. Cohen served as an Interim Chief Executive Officer at Celsus Therapeutics Plc. He served as a Director of Celsus Therapeutics Plc from January 12, 2005 to December 10, 2013. Dr. Cohen worked in the laboratories of Wolf Brandt (University of Cape Town) and Dietrich Averbeck (Curie Institute) on chromatin and DNA repair processes. He is also a recipient of a certificate in Business Management and Entrepreneurship from the Cape Technikon (awarded with distinction, 2002). Dr. Cohen Awards includes: Amelia Schenkman Foundation Merit bursary, Dean's List, Foundation for Research and Development bursary, Boursier du Gouvernement Français (French Ministry of Foreign Affairs), Young Scientist travel award Brussels 2001 (L-MOV), San Francisco 2000 (ASP). Dr. Cohen holds Israeli and South African nationalities and is fluent in English, French, Hebrew and Romanian. He holds BS in Microbiology and Biochemistry from University of Cape Town. Dr. Cohen holds a PhD (cum laude) from the Curie Institute and the University of Paris V in Medical Science.

CEO Compensation
  • Yuval's compensation has increased whilst company is loss making.
  • Yuval's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Corbus Pharmaceuticals Holdings management team in years:

4.8
Average Tenure
60
Average Age
  • The tenure for the Corbus Pharmaceuticals Holdings management team is about average.
Management Team

Yuval Cohen

TITLE
CEO & Director
COMPENSATION
$3M
AGE
43
TENURE
5 yrs

Sean Moran

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
60
TENURE
5 yrs

Mark Tepper

TITLE
Co-Founder & Consultant
COMPENSATION
$1M
AGE
61

Barbara White

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
68
TENURE
4.7 yrs

Ted Jenkins

TITLE
Senior Director of Investor Relations & Communications

Scott Constantine

TITLE
Senior Director & Head of Clinical Operations

Craig Millian

TITLE
Chief Commercial Officer
AGE
50
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Corbus Pharmaceuticals Holdings board of directors in years:

4.3
Average Tenure
46
Average Age
  • The tenure for the Corbus Pharmaceuticals Holdings board of directors is about average.
Board of Directors

Alan Holmer

TITLE
Chairman
COMPENSATION
$225K
AGE
68
TENURE
5 yrs

Yuval Cohen

TITLE
CEO & Director
COMPENSATION
$3M
AGE
43
TENURE
5 yrs

Chip Catlin

TITLE
Director
COMPENSATION
$208K
AGE
70
TENURE
4.7 yrs

Paris Panayiotopoulos

TITLE
Director
COMPENSATION
$372K
AGE
44
TENURE
1.5 yrs

George Kunos

TITLE
Member of Scientific Advisory Board
TENURE
0.6 yrs

David Hochman

TITLE
Director
COMPENSATION
$195K
AGE
43
TENURE
5.3 yrs

Charles Serhan

TITLE
Member of Scientific Advisory Board
TENURE
3.9 yrs

Michael Knowles

TITLE
Member of Scientific Advisory Board

John Jenkins

TITLE
Director
AGE
60
TENURE
0.8 yrs

Rachelle Jacques

TITLE
Director
AGE
46
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Corbus Pharmaceuticals Holdings insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 19 Buy David Hochman Individual 15. Mar 19 15. Mar 19 2,000 €6.16 €12,327
15. Mar 19 Buy John Jenkins Individual 15. Mar 19 15. Mar 19 1,000 €6.16 €6,163
15. Mar 19 Buy Craig Millian Individual 14. Mar 19 14. Mar 19 5,000 €6.06 €30,312
14. Mar 19 Buy Barbara White Individual 14. Mar 19 14. Mar 19 4,638 €5.72 €26,539
14. Mar 19 Buy Sean Moran Individual 14. Mar 19 14. Mar 19 1,500 €5.90 €8,852
14. Mar 19 Buy Yuval Cohen Individual 14. Mar 19 14. Mar 19 1,530 €5.74 €8,786
16. May 18 Buy Barbara White Individual 15. May 18 15. May 18 2,586 €4.95 €12,789
16. May 18 Buy Yuval Cohen Individual 15. May 18 15. May 18 1,725 €4.93 €8,505
15. May 18 Buy David Hochman Individual 14. May 18 14. May 18 5,000 €4.57 €22,872
15. May 18 Buy Sean Moran Individual 15. May 18 15. May 18 4,000 €4.86 €19,452
X
Management checks
We assess Corbus Pharmaceuticals Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corbus Pharmaceuticals Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Details
Name: Corbus Pharmaceuticals Holdings, Inc.
337
Exchange: DB
Founded: 2009
$397,881,434
64,455,221
Website: http://www.corbuspharma.com
Address: Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive,
Norwood,
Massachusetts, 02062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CRBP New Common Shares Nasdaq Global Market US USD 27. Oct 2014
DB 337 New Common Shares Deutsche Boerse AG DE EUR 27. Oct 2014
LSE 0SZI New Common Shares London Stock Exchange GB USD 27. Oct 2014
Number of employees
Current staff
Staff numbers
77
Corbus Pharmaceuticals Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:28
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.